Princebuild joins INBS’ portfolio of over 400 accounts in 19 countries as the Company plans to enter the US market
NEW YORK, December 18, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS
The data from our pharmacokinetic (PK) study shows that fingerprint sweat mimics the rate and extent of codeine in blood
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed
Digital Marketing Initiatives to Highlight Innovative Non-Invasive Drug Screening Technology and Market Expansion Plans NEW YORK, October 31, 2024 –
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary
Developer Praises Intelligent Bio Solutions’ Innovative Drug Testing Solution for Improving Workplace Safety NEW YORK, October 24, 2024 – Intelligent
Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity NEW YORK, October 14, 2024
NEW YORK, October 09, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
New York, October 01, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
New York, September 27, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
New York, September 25, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Fourth-quarter revenue of $0.73 million, up 64% year-over-year Full-year revenue of $3.11 million, up 148% year-over-year As of June 30,
